Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Knight Therapeutics stock

GUD.TO
CA4990531069
A1XE7A

Price

5.31 CAD
Today +/-
-0.03 CAD
Today %
-0.91 %

Knight Therapeutics stock price

CAD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Knight Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Knight Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Knight Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Knight Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Knight Therapeutics Stock Price History

DateKnight Therapeutics Price
12/5/20245.31 CAD
12/4/20245.36 CAD
12/3/20245.39 CAD
12/2/20245.34 CAD
11/29/20245.27 CAD
11/28/20245.22 CAD
11/27/20245.27 CAD
11/26/20245.29 CAD
11/25/20245.27 CAD
11/22/20245.29 CAD
11/21/20245.30 CAD
11/20/20245.21 CAD
11/19/20245.15 CAD
11/18/20245.37 CAD
11/15/20245.19 CAD
11/14/20245.20 CAD
11/13/20245.14 CAD
11/12/20245.11 CAD
11/11/20245.17 CAD
11/8/20245.26 CAD
11/7/20245.15 CAD
11/6/20245.74 CAD

Knight Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Knight Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Knight Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Knight Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Knight Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Knight Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Knight Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Knight Therapeutics’s growth potential.

Knight Therapeutics Revenue, EBIT and net profit per share

DateKnight Therapeutics RevenueKnight Therapeutics EBITKnight Therapeutics Net Income
2029e490.91 M CAD0 CAD32.69 M CAD
2028e466.69 M CAD0 CAD30.65 M CAD
2027e436.8 M CAD0 CAD23.5 M CAD
2026e403.52 M CAD-2.75 M CAD12.22 M CAD
2025e367.38 M CAD17.69 M CAD8.35 M CAD
2024e365.35 M CAD11.01 M CAD-5.09 M CAD
2023328.2 M CAD6.37 M CAD-16.84 M CAD
2022293.56 M CAD-17.06 M CAD-29.89 M CAD
2021243.48 M CAD-12.83 M CAD15.68 M CAD
2020199.5 M CAD-26.3 M CAD42.1 M CAD
201947.5 M CAD-4.7 M CAD14.5 M CAD
201812.5 M CAD-5.8 M CAD24.1 M CAD
20178.6 M CAD-8.9 M CAD17.2 M CAD
20165.9 M CAD-3.9 M CAD18.6 M CAD
20151 M CAD-9.1 M CAD34.2 M CAD
2014400,000 CAD-4.6 M CAD125.9 M CAD

Knight Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M CAD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M CAD)NET INCOME (M CAD)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
01581247199243293328365367403436466490
--400.0060.0050.00291.67323.4022.1120.5811.9511.280.559.818.196.885.15
-15,200.0080.0087.5083.3355.3240.7047.3347.1046.3441.6441.4237.7234.8632.6231.02
0047102681115138152000000
12534181724144215-29-16-5812233032
--72.80-47.06-5.5641.18-41.67200.00-64.29-293.33-44.83-68.75-260.0050.0091.6730.436.67
57.396.5121.3143.4143.3140.1132124.52114.89107.47000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Knight Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Knight Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CAD)RECEIVABLES (M CAD)OTHER REC. (M CAD)INVENTORIES (M CAD)OTHER CURRENT LIAB. (M CAD)CURRENT ASSETS (M CAD)TANGIBLE ASSETS (M CAD)LONG-T. INVEST. (M CAD)LONG-T. REC. (M CAD)INTANGIBLE ASSETS (M CAD)GOODWILL (M CAD)OTHER NON-CURRENT ASSETS (M CAD)NON-CURRENT ASSETS (M CAD)TOTAL ASSETS (B CAD)LIABILITIESCOMMON STOCK (M CAD)ADDITIONAL PAID-IN CAPITAL (M CAD)RETAINED EARNINGS (M CAD)OTHER EQUITY (M CAD)UNREAL. GAINS/LOSSES (M CAD)EQUITY (B CAD)LIABILITIES (M CAD)PROVISIONS (M CAD)OTHER SHORT-TERM LIAB. (M CAD)SHORT-TERM DEBTS (M CAD)LONG-TERM DEBT PORTION (M CAD)SHORT-TERM REC. (M CAD)LONG-T. LIAB. (M CAD)DEFERRED TAXES (M CAD)OTHER LIAB. (M CAD)LONG-T. LIABILITIES (M CAD)DEBT (M CAD)TOTAL CAPITAL (B CAD)
2014201520162017201820192020202120222023
                   
426.9494.8787.8787.9703.8427.7411.2162.7191.04157.83
0.10.42.62.12.9103.562.555.3994.8988.72
0.92.47.96.88.68.219.512.0315.3221.54
0.61.50.81.21.170.956.572.492.4991.83
00.40.61.1111.22.42.451.885.18
428.5499.5799.7799.1717.4621.5552.1304.97395.62365.12
0000.60.82926.229.9422.6317.86
19.9106.6170.8189289.7260175.1179.41156.09116.36
35.732.30023.346.341.743.4343.8549.2
0.83.314.212.617.5173.4156.5350.3338.78289.96
0000088.377.775.482.2779.84
1.67.26.14.7386.810.38.4415.627.16
58149.4191.1206.9334.3683.8487.5686.92659.22580.38
0.490.650.991.011.051.311.040.991.050.95
                   
341.1439.1760.4761.5761.8723.8694.4628.85599.06540.05
2.16.89.512.214.316.518.721.7823.6625.99
125.9160.2179.4196.6232.953174.7191.76161.87151.01
3.222.115.41.133.225.977.8649.3938.24
6.813.91519.9-12.2-8.4-8.5-8.24-8.13-8.41
0.480.640.980.991.030.810.890.840.830.75
0.600.70.50.872.844.565.31106.0685.37
1.52.42.54.55.321.60000
5.54.36.69.211.1204.115.911.7215.019.09
0000000000
0000052.353.628.2820.2519.58
7.66.79.814.217.2350.8114105.3141.32114.03
000009.82.512.6857.4549.51
00.200027.921.612.374.372.82
001.30.54.61.715.219.5225.8532.26
00.21.30.54.639.439.344.5787.6684.59
7.66.911.114.721.8390.2153.3149.87228.98198.62
0.490.650.991.011.051.21.040.991.050.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Knight Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Knight Therapeutics's financial health and stability.

Assets

Knight Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Knight Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Knight Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Knight Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CAD)DEPRECIATION (M CAD)DEFERRED TAXES (M CAD)CHANGES IN WORKING CAPITAL (M CAD)NON-CASH ITEM (M CAD)PAID INTEREST (M CAD)PAID TAXES (M CAD)NET CASH FLOW FROM OPERATING ACTIVITIES (M CAD)CAPITAL EXPENDITURES (M CAD)CASH FLOW FROM INVESTING ACTIVITIES (M CAD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CAD)INTEREST INCOME AND EXPENSES (M CAD)NET DEBT CHANGE (M CAD)NET CHANGE IN EQUITY (M CAD)CASH FLOW FROM FINANCING ACTIVITIES (M CAD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (CAD)TOTAL DIVIDENDS PAID (M CAD)NET CHANGE IN CASH FLOW (M CAD)FREE CASH FLOW (M CAD)SHARE-BASED COMPENSATION (M CAD)
2014201520162017201820192020202120222023
12534181724183115-29-16
00011432476250
000210-2-7-17-9
4-318-23-10-23-2-8-26
-130-23-6-5-10-8-50-93738
0000021249
0173026855
071423-54-12444535
0-1-90-3-2-20-224-25-9
-49-67-49-39-252-11101-105-6329
-49-65-39-39-248-8122118-3739
0000000000
00000-86-1431-18
3281331300-54-36-64-30-53
3281331300-62-29-78-2-81
---------4.00-9.00
0000000000
283-45277-18-251-7055-143-14-12
0.735.894.8823.33-9.611.65-32.88-179.5719.1825.98
0000000000

Knight Therapeutics stock margins

The Knight Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Knight Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Knight Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Knight Therapeutics's sales revenue. A higher gross margin percentage indicates that the Knight Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Knight Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Knight Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Knight Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Knight Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Knight Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Knight Therapeutics Margin History

Knight Therapeutics Gross marginKnight Therapeutics Profit marginKnight Therapeutics EBIT marginKnight Therapeutics Profit margin
2029e46.51 %0 %6.66 %
2028e46.51 %0 %6.57 %
2027e46.51 %0 %5.38 %
2026e46.51 %-0.68 %3.03 %
2025e46.51 %4.81 %2.27 %
2024e46.51 %3.01 %-1.39 %
202346.51 %1.94 %-5.13 %
202247.03 %-5.81 %-10.18 %
202147.4 %-5.27 %6.44 %
202040.95 %-13.18 %21.1 %
201956.63 %-9.89 %30.53 %
201882.4 %-46.4 %192.8 %
201781.4 %-103.49 %200 %
201674.58 %-66.1 %315.25 %
201560 %-910 %3,420 %
201446.51 %-1,150 %31,475 %

Knight Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Knight Therapeutics earnings per share therefore indicates how much revenue Knight Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Knight Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Knight Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Knight Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Knight Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Knight Therapeutics Revenue, EBIT and net profit per share

DateKnight Therapeutics Sales per ShareKnight Therapeutics EBIT per shareKnight Therapeutics Earnings per Share
2029e4.87 CAD0 CAD0.32 CAD
2028e4.63 CAD0 CAD0.3 CAD
2027e4.33 CAD0 CAD0.23 CAD
2026e4 CAD0 CAD0.12 CAD
2025e3.64 CAD0 CAD0.08 CAD
2024e3.62 CAD0 CAD-0.05 CAD
20233.05 CAD0.06 CAD-0.16 CAD
20222.56 CAD-0.15 CAD-0.26 CAD
20211.96 CAD-0.1 CAD0.13 CAD
20201.51 CAD-0.2 CAD0.32 CAD
20190.34 CAD-0.03 CAD0.1 CAD
20180.09 CAD-0.04 CAD0.17 CAD
20170.06 CAD-0.06 CAD0.12 CAD
20160.05 CAD-0.03 CAD0.15 CAD
20150.01 CAD-0.09 CAD0.35 CAD
20140.01 CAD-0.08 CAD2.2 CAD

Knight Therapeutics business model

Knight Therapeutics Inc is a Canadian biopharmaceutical company that was founded in 2014. The company is listed on the Toronto Stock Exchange and NASDAQ, making it accessible to all investors. The company's business philosophy is based on the "Acquire and Develop" model, which involves developing acquired products or products that were previously in the approval phase for market testing. Knight Therapeutics focuses on the development and commercialization of pharmaceutical products in Latin America and Canada. The company has gained overseas experience by signing long-term agreements with significant international pharmaceutical companies, including a Japanese and a South Korean pharmaceutical company. In Canada, Knight is in a position to meet the increased demand for innovative drug research and provide patients with important therapies. In Latin America, they focus on achieving broader access to innovative drugs. In this regard, the company is actively working to expand its portfolio of safe, high-quality, and effective medications for this region. The company's product range includes a wide range of priority pharmaceutical areas such as cancer treatments, eye diseases, cardiology, infectious diseases, and pain relief. The company has the expertise to manufacture and distribute specialized treatment options for many diseases, such as cancer and rare diseases. One of Knight Therapeutics' most well-known products is the drug Probuphine. It was approved by the US Food and Drug Administration in May 2016 to help patients with opioid dependence. Knight acquired the product under license from the manufacturer Braeburn Pharmaceuticals. Permian LLC, a real estate fund specializing in retail properties, attempted to acquire Knight with a $150 per share offer. However, this deal was rejected due to Knight's stock dilutions. Another important product of the company is Neuragen, which is used for neuropathic pain and fibromyalgia. It is currently approved in Canada and Brazil, but approvals in the US and other countries are also being sought. Furthermore, Knight Therapeutics is also involved in the manufacturing of generic narcotics and has already concluded some potentially profitable contracts to introduce these products into the Latin American pharmaceutical market. The company has also signed an extremely promising agreement with SAI Life Sciences to develop compounds for the treatment of pain and inflammation. Knight Therapeutics' roadmap also includes a strong partnership with Canadian company Triumvira Immunologics for the further development of cancer treatments, as well as a collaboration with Endoceutics to introduce Prasterone, a superior treatment for vaginal atrophy, menopausal symptoms, and hot flashes in women, to increase bone density and improve sexual life. Overall, Knight Therapeutics has a solid reputation as an emerging player in the pharmaceutical market and is known for its advanced research and development of drugs, with a particular focus on oncology, ophthalmology, and cardiology. It remains to be seen how the company will develop in the future, but it appears that with the aggressive development of innovative products and the expansion into new markets, Knight has great potential to increase its market share in the pharmaceutical industry as a whole. Knight Therapeutics is one of the most popular companies on Eulerpool.com.

Knight Therapeutics SWOT Analysis

Strengths

Knight Therapeutics Inc. has several key strengths that contribute to its success in the pharmaceutical industry:

  • Strong portfolio of innovative and differentiated products.
  • Strategic partnerships and collaborations with global pharmaceutical companies.
  • Excellent research and development capabilities.
  • Strong financial position and stable revenue streams.
  • Efficient and effective supply chain management.

Weaknesses

Despite its strengths, Knight Therapeutics Inc. also faces certain weaknesses that pose challenges:

  • Limited geographical presence and market reach.
  • Relatively small product portfolio compared to larger competitors.
  • Dependency on a few key products for a significant portion of revenue.
  • Lack of in-house manufacturing capabilities.
  • Vulnerable to changes in regulatory environments.

Opportunities

Knight Therapeutics Inc. has various opportunities to capitalize on in the pharmaceutical industry:

  • Expanding into new markets through strategic partnerships and acquisitions.
  • Increasing demand for innovative treatments and therapies.
  • Advancements in technology that enhance research and development efforts.
  • Growing prevalence of chronic diseases demanding effective medicines.
  • Increasing healthcare expenditure, particularly in emerging markets.

Threats

Knight Therapeutics Inc. should be aware of potential threats that could impact its business:

  • Intense competition from larger pharmaceutical companies.
  • Uncertainty surrounding regulatory approvals and drug pricing.
  • Market saturation in certain therapeutic areas.
  • Possible infringement on intellectual property rights.
  • Fluctuations in currency exchange rates affecting international operations.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Knight Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Knight Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Knight Therapeutics shares outstanding

The number of shares was Knight Therapeutics in 2023 — This indicates how many shares 107.466 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Knight Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Knight Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Knight Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Knight Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Knight Therapeutics.

Knight Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.02 CAD0 CAD (-100 %)2024 Q3
6/30/20240.02 CAD-0.02 CAD (-199.01 %)2024 Q2
3/31/20240.01 CAD-0.04 CAD (-697.01 %)2024 Q1
12/31/2023-0.02 CAD-0.23 CAD (-1,163.74 %)2023 Q4
9/30/2023-0.04 CAD0.09 CAD (305.48 %)2023 Q3
6/30/2023-0.01 CAD0.02 CAD (258.73 %)2023 Q2
3/31/2023-0.06 CAD-0.04 CAD (37.5 %)2023 Q1
12/31/2022-0.08 CAD-0.13 CAD (-54.39 %)2022 Q4
9/30/2022-0.05 CAD0.01 CAD (121.98 %)2022 Q3
6/30/2022-0.02 CAD0.02 CAD (190.09 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Knight Therapeutics stock

Eulerpool World ESG Rating (EESG©)

26/ 100

🌱 Environment

5

👫 Social

27

🏛️ Governance

45

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Knight Therapeutics shareholders

%
Name
Stocks
Change
Date
20.59535 % Long Zone Holdings, Inc.20,760,733-918,0005/28/2024
12.16789 % G2S2 Capital Inc12,265,6001,064,3001/31/2024
11.41518 % Medici Strategic Portfolio Management Inc11,506,84411,506,8444/28/2023
6.17401 % QV Investors Inc.6,223,58408/31/2024
1.07743 % Dimensional Fund Advisors, L.P.1,086,07718,2007/31/2024
0.99488 % Goodman (Jonathan Ross)1,002,8676,1966/15/2024
0.80929 % DFA Australia Ltd.815,792-27/31/2024
0.69442 % Fidelity Investments Canada ULC700,000-457,1006/30/2024
0.40775 % Bessemer Trust Company, N.A. (US)411,02507/31/2024
0.39384 % North Growth Management Ltd.397,00006/30/2023
1
2
3
4
5
...
8

Knight Therapeutics Executives and Management Board

Ms. Samira Sakhia

(54)
Knight Therapeutics President, Chief Executive Officer, Director (since 2016)
Compensation 1.17 M CAD

Mr. Arvind Utchanah

Knight Therapeutics Chief Financial Officer
Compensation 801,676 CAD

Ms. Amal Khouri

Knight Therapeutics Chief Business Officer
Compensation 719,087 CAD

Mr. Stephani Saverio

Knight Therapeutics Global Vice President - Business Development
Compensation 550,380 CAD

Mr. Jeff Martens

Knight Therapeutics Global Vice President - Commercial
Compensation 534,147 CAD
1
2
3

Knight Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Profound Medical Stock
Profound Medical
SupplierCustomer0,760,340,35-0,28-0,320,05
Synergy CHC Stock
Synergy CHC
SupplierCustomer0,43 0,090,10
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,42-0,06-0,53 0,140,09
Titan Pharmaceuticals Stock
Titan Pharmaceuticals
SupplierCustomer0,35-0,070,42-0,08-0,320,91
Jaguar Health Stock
Jaguar Health
SupplierCustomer0,300,09-0,04-0,40-0,37-0,22
Biotoscana Investments S.A. Stock
Biotoscana Investments S.A.
SupplierCustomer0,23 0,29-0,39-0,26-0,60
Advaxis Stock
Advaxis
SupplierCustomer0,18-0,040,31-0,38-0,390,19
Onconova Therapeutics Stock
Onconova Therapeutics
SupplierCustomer0,13-0,15-0,10-0,46-0,360,30
Antibe Therapeutics Stock
Antibe Therapeutics
SupplierCustomer0,110,06-0,270,01-0,320,33
Alimera Sciences Stock
Alimera Sciences
SupplierCustomer0,10 -0,39-0,13-0,35-0,15
1

Most common questions regarding Knight Therapeutics

What values and corporate philosophy does Knight Therapeutics represent?

Knight Therapeutics Inc represents values of integrity, innovation, and collaboration. With a corporate philosophy focused on delivering innovative pharmaceutical solutions, Knight Therapeutics is committed to improving patient outcomes and making a positive impact on global health. The company prioritizes ethical business practices, ensuring transparency and reliability in all its operations. Knight Therapeutics Inc emphasizes building strong partnerships with healthcare professionals and stakeholders to achieve shared goals. By consistently upholding its values and corporate philosophy, Knight Therapeutics Inc strives to be a trusted leader in the pharmaceutical industry.

In which countries and regions is Knight Therapeutics primarily present?

Knight Therapeutics Inc is primarily present in Canada, where it is headquartered in Quebec. As a specialty pharmaceutical company, Knight Therapeutics focuses on acquiring, developing, and commercializing innovative prescription drugs. With a strategic focus on Canada, the company also operates in other regions, including the United States and select European countries. As Knight Therapeutics continues to expand its presence and partnerships in the pharmaceutical industry, it aims to bring innovative therapies to patients worldwide.

What significant milestones has the company Knight Therapeutics achieved?

Some significant milestones achieved by Knight Therapeutics Inc include expanding its product portfolio through strategic licensing agreements, successfully completing several clinical trials, and securing regulatory approvals for its pharmaceutical products in various markets. The company has also demonstrated strong financial performance, achieving consistent revenue growth and generating positive cash flow. Knight Therapeutics Inc has established partnerships with world-class pharmaceutical companies to leverage their expertise and expand its global reach. Furthermore, the company has made notable progress in advancing its pipeline of innovative therapies, aimed at addressing unmet medical needs and improving patient outcomes.

What is the history and background of the company Knight Therapeutics?

Knight Therapeutics Inc. is a leading Canadian specialty pharmaceutical company established in 2014. Headquartered in Montreal, Quebec, Knight focuses on acquiring and commercializing innovative pharmaceutical products for the Canadian and international markets. With a mission to improve patient care by providing novel treatment options, Knight Therapeutics collaborates with global partners to bring cutting-edge therapies to market. The company's portfolio includes a diverse range of therapeutic areas such as oncology, mental health, and rare diseases. Known for its strategic management and growth-oriented approach, Knight Therapeutics is committed to delivering high-quality pharmaceuticals that address unmet medical needs and enhance healthcare outcomes.

Who are the main competitors of Knight Therapeutics in the market?

The main competitors of Knight Therapeutics Inc in the market include other pharmaceutical companies such as Valeo Pharma Inc, Cipher Pharmaceuticals Inc, and Crescita Therapeutics Inc.

In which industries is Knight Therapeutics primarily active?

Knight Therapeutics Inc is primarily active in the pharmaceutical industry. As a Canadian specialty pharmaceutical company, Knight Therapeutics focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and international markets. With a diverse portfolio, the company primarily operates in areas such as intellectual property-protected medicines, biotechnology products, and specialty pharmaceuticals. Knight Therapeutics strives to collaborate with global partners to bring novel therapies to patients, contributing to improved healthcare outcomes. Through its activities in the pharmaceutical industry, Knight Therapeutics aims to address unmet medical needs and provide innovative solutions for patients worldwide.

What is the business model of Knight Therapeutics?

The business model of Knight Therapeutics Inc. is focused on acquiring or in-licensing innovative pharmaceutical products and commercializing them in Canada and other global markets. Knight's strategy involves partnering with established pharmaceutical companies or academic institutions to access a diverse range of therapeutics and medical devices. By focusing on products that are either proven or have a high probability of regulatory approval, Knight aims to bring innovative treatments to patients and generate sustainable revenue growth. With its expertise in regulatory affairs, marketing, and distribution, Knight Therapeutics Inc. aims to optimize the value of its portfolio and deliver long-term value to shareholders.

What is the P/E ratio of Knight Therapeutics 2024?

The Knight Therapeutics P/E ratio is -112.13.

What is the P/S ratio of Knight Therapeutics 2024?

The Knight Therapeutics P/S ratio is 1.56.

What is the Quality Investing of Knight Therapeutics?

The Quality Investing for Knight Therapeutics is 3/10.

What is the revenue of Knight Therapeutics 2024?

The expected Knight Therapeutics revenue is 365.35 M CAD.

How high is the profit of Knight Therapeutics 2024?

The expected Knight Therapeutics profit is -5.09 M CAD.

What is the business model of Knight Therapeutics

Knight Therapeutics Inc is a Canadian biopharmaceutical company that specializes in the development and marketing of innovative medicines. The company focuses on five main areas: infectious diseases, pain management, oncology, ophthalmology, and neuropsychiatric disorders. It works closely with leading research institutes and companies to find innovative approaches for these diseases and improve treatment options. Knight Therapeutics offers medication for life-threatening infections such as HIV, hepatitis, and tuberculosis, as well as tailored pain medications. It also develops therapies for cancer treatment, eye diseases, and neuropsychiatric disorders. Overall, Knight Therapeutics specializes in developing and marketing innovative medicines, working with research institutes and having a strong presence in the North American market. Its goal is to improve the lives of millions of people worldwide and contribute to medical research and development.

What is the Knight Therapeutics dividend?

Knight Therapeutics pays a dividend of 0 CAD distributed over payouts per year.

How often does Knight Therapeutics pay dividends?

The dividend cannot currently be calculated for Knight Therapeutics or the company does not pay out a dividend.

What is the Knight Therapeutics ISIN?

The ISIN of Knight Therapeutics is CA4990531069.

What is the Knight Therapeutics WKN?

The WKN of Knight Therapeutics is A1XE7A.

What is the Knight Therapeutics ticker?

The ticker of Knight Therapeutics is GUD.TO.

How much dividend does Knight Therapeutics pay?

Over the past 12 months, Knight Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Knight Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Knight Therapeutics?

The current dividend yield of Knight Therapeutics is .

When does Knight Therapeutics pay dividends?

Knight Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Knight Therapeutics?

Knight Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Knight Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Knight Therapeutics located?

Knight Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Knight Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Knight Therapeutics from 12/5/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did Knight Therapeutics pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of Knight Therapeutics in the year 2023?

In the year 2023, Knight Therapeutics distributed 0 CAD as dividends.

In which currency does Knight Therapeutics pay out the dividend?

The dividends of Knight Therapeutics are distributed in CAD.

All fundamentals about Knight Therapeutics

Our stock analysis for Knight Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Knight Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.